Haifei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haifei Liu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Ruoqu Wei
Dermatology Center, Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China
3 shared publications - Yijun Yang
Department of Dermatology, Xinhua Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China
3 shared publications Chaolan Pan
Department of Dermatology, Xinhua Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China
2 shared publications- Jiawen Chen
Department of Dermatology, Xinhua Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China
2 shared publications - Yumeng Wang
Institute of Dermatology, Shanghai Jiaotong University School of Medicine , Shanghai
2 shared publications - Zhen Zhang
Department of Dermatology Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China
2 shared publications
Latest Publications
- 17 August 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (8) , e70152
Platelet‐Derived Extracellular Vesicles Alleviate Psoriatic Inflammation via Mitochondrial Transfer to Macrophages
Platelet‐rich plasma (PRP) is a safe, autologous plasma component abundant in cytokines and extracellular vesicles, frequently applied to treat inflammatory disorders. Although PRP demonstrates potential for psoriasis therapy, its underlying mechanism remains insufficiently understood. In this study, various PRP constituents were evaluated in an imiquimod (IMQ)‐induced mouse model of psoriasis. PRP, platelet‐derived extracellular vesicles (PEVs), and platelet‐poor plasma (PPP) were isolated from mice and administered subcutaneously. The data showed that PEVs, rather than PPP, served as the principal anti‐psoriatic factor. Furthermore, RNA sequencing and flow cytometry revealed that PEVs markedly suppressed M1 polarisation of macrophages, thereby mitigating psoriatic‐like inflammation. In vitro, PEVs delivered encapsulated mitochondria to RAW264.7 cells in a concentration‐dependent manner. These functional organelles enhanced oxidative phosphorylation and suppressed glycolysis, driving a metabolic shift favouring an anti‐inflammatory phenotype and attenuating the inflammatory response. In conclusion, PEVs emerge as the primary PRP component responsible for inflammatory suppression in psoriasis. Notably, mitochondria transfer mediated by PEVs underscores a promising therapeutic avenue and provides novel insight into the role of platelet derivatives in inflammatory diseases.
- 17 August 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (8) , e70152
Platelet‐Derived Extracellular Vesicles Alleviate Psoriatic Inflammation via Mitochondrial Transfer to Macrophages
Platelet‐rich plasma (PRP) is a safe, autologous plasma component abundant in cytokines and extracellular vesicles, frequently applied to treat inflammatory disorders. Although PRP demonstrates potential for psoriasis therapy, its underlying mechanism remains insufficiently understood. In this study, various PRP constituents were evaluated in an imiquimod (IMQ)‐induced mouse model of psoriasis. PRP, platelet‐derived extracellular vesicles (PEVs), and platelet‐poor plasma (PPP) were isolated from mice and administered subcutaneously. The data showed that PEVs, rather than PPP, served as the principal anti‐psoriatic factor. Furthermore, RNA sequencing and flow cytometry revealed that PEVs markedly suppressed M1 polarisation of macrophages, thereby mitigating psoriatic‐like inflammation. In vitro, PEVs delivered encapsulated mitochondria to RAW264.7 cells in a concentration‐dependent manner. These functional organelles enhanced oxidative phosphorylation and suppressed glycolysis, driving a metabolic shift favouring an anti‐inflammatory phenotype and attenuating the inflammatory response. In conclusion, PEVs emerge as the primary PRP component responsible for inflammatory suppression in psoriasis. Notably, mitochondria transfer mediated by PEVs underscores a promising therapeutic avenue and provides novel insight into the role of platelet derivatives in inflammatory diseases.
- 20 April 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (1) , e13-e16
Exploring Th17‐related inflammation in AP1B1‐associated KIDAR syndrome and potential therapeutic implications of secukinumab
- 20 April 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (1) , e13-e16
Exploring Th17‐related inflammation in AP1B1‐associated KIDAR syndrome and potential therapeutic implications of secukinumab
- Open Access
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 1) , S79-S83
Coexistence of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Dermatomyositis in a 12-Year-Old Boy
Wei R, et al. Ann Dermatol. 2023 May;35:e49. https://doi.org/10.5021/ad.20.310
- 1 January 2023
- Published by XMLink in Annals of Dermatology
- Vol. 35 (Suppl 1) , S79-S83
Open AccessCoexistence of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Dermatomyositis in a 12-Year-Old Boy
Wei R, et al. Ann Dermatol. 2023 May;35:e49. https://doi.org/10.5021/ad.20.310
- 7 November 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (3) , 401-406
Successful treatment with secukinumab of psoriasis‐like dermatitis in a patient with holocarboxylase synthetase deficiency
Holocarboxylase synthetase deficiency (HSD) is a rare autosomal recessive disorder of biotin metabolism. Typical manifestations include irreversible metabolic disorders and erythroderma‐like dermatitis. Most patients respond well to biotin supplementation. Psoriasis‐like phenotype associated with this disease has been rarely reported in the literature and experiences with the use of biologics in patients with HSD are still lacking. We reported a rare case of recurrent psoriasis‐like skin lesions in a 6‐year‐old child with HSD. The patient did not respond to initial therapy with high‐dose oral biotin. Immunofluorescence staining showed an increased number of interleukin (IL)‐17A+ cells in his skin lesions. Based on this finding, the patient was successfully treated with human anti‐IL‐17A monoclonal antibody (secukinumab). He did not report any side effects and remained healthy during the 2‐year follow‐up. We provide a comprehensive review of the reported cases of HSD with psoriasis‐like dermatitis to date. The psoriasis‐like phenotype of HSD is controversial in treatment and IL‐17A inhibitor is an alternative therapeutic option.
- 7 November 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (3) , 401-406
Successful treatment with secukinumab of psoriasis‐like dermatitis in a patient with holocarboxylase synthetase deficiency
Holocarboxylase synthetase deficiency (HSD) is a rare autosomal recessive disorder of biotin metabolism. Typical manifestations include irreversible metabolic disorders and erythroderma‐like dermatitis. Most patients respond well to biotin supplementation. Psoriasis‐like phenotype associated with this disease has been rarely reported in the literature and experiences with the use of biologics in patients with HSD are still lacking. We reported a rare case of recurrent psoriasis‐like skin lesions in a 6‐year‐old child with HSD. The patient did not respond to initial therapy with high‐dose oral biotin. Immunofluorescence staining showed an increased number of interleukin (IL)‐17A+ cells in his skin lesions. Based on this finding, the patient was successfully treated with human anti‐IL‐17A monoclonal antibody (secukinumab). He did not report any side effects and remained healthy during the 2‐year follow‐up. We provide a comprehensive review of the reported cases of HSD with psoriasis‐like dermatitis to date. The psoriasis‐like phenotype of HSD is controversial in treatment and IL‐17A inhibitor is an alternative therapeutic option.